Table 1.
The baseline variables in the two groups, and the peri-procedure and late outcomes.
| Mean (SD), median (range), n (%) | Transurethral deroofing | Transrectal needle aspiration | P |
|---|---|---|---|
| Baseline | |||
| Number of patients | 30 | 12 | |
| Age at intervention (years) | 49.4 (14) | 55.4 (15) | 0.2 |
| Body mass index, kg/m2 | 28.6 (5.0) | 28.4 (5.3) | 0.8 |
| Diabetes mellitus | 15 (50) | 4 | 0.5 |
| Patients with system failure: | 0.5 | ||
| End-stage kidney disease | 3 (10) | – | |
| Liver cell failure | 3 (10) | 1 | |
| Indwelling urethral catheter | 9 (30) | 3 | 1 |
| Systemic chemo/immunosuppressive therapy | 6 (20) | 4 | 0.79 |
| Recent urethral instrumentation | 4 (13) | 3 | 0.03 |
| Recent prostate needle biopsy | – | 1 | 0.25 |
| Presentation | 0.51 | ||
| Exacerbating LUTs | 12 (40) | 8 | |
| Acute urine retention | 9 (30) | 1 | |
| Indwelling catheter with systemic and | 9 (30) | 3 | |
| local symptoms | |||
| PSA at presentation (ng/mL) | 1.7 (0.1–4.7) | 4.4 (0.8–50) | 0.12 |
| Leukocyte count at presentation (/mL) | 12.1 (4.8–16.7) | 12.5 (5.2–29) | 0.63 |
| Positive urine culture at presentation | 12 (40) | 5 | 0.37 |
| TRUS/MRI prostate size (mL) | 53 (6.2–110) | 70 (21–106) | 0.5 |
| TRUS/MRI abscess size (mL) | 4.5 (2–23) | 2.7 (1.5–7.1) | 0.2 |
| Prostate size group | 1 | ||
| TRUS/MRI prostate size (< 80 mL) | 7 (23) | 3 | |
| TRUS/MRI prostate size (> 80 mL) | 23 (77) | 9 | |
| Location of the abscess in the prostate | 0.06 | ||
| Right lobe | 9 (30) | 1 | |
| Left lobe | 6 (20) | 5 | |
| Multiple sites | 15 (50) | 6 | |
| Peri-procedure and late outcomes | |||
| Catheter after procedure | <0.001 | ||
| Urethral catheter | 26 (87) | 2 | |
| Suprapubic catheter | 2 (7) | 2 | |
| Both | 2 (7) | – | |
| Hospital stay (days) | 2 (1–11) | 1 (1–19) | 0.04 |
| Need for re-treatment for the abscess | 2 (7) | – | 1 |
| Need for re-treatment for the prostate | 14 (47) | 6 | 0.4 |
| α-blockers | 12 (40) | 2 | |
| TURP | 2 (7) | 2 | |
| Holmium laser enucleation of the prostate | – | 1 | |
| Androgen deprivation for prostate cancer | – | 1 | |
| Complications: Clavien grade/treatment offered | 0.1 | ||
| Septic shock/IVa/Antimicrobial + inotropics | 2 (7) | – | |
| Urethral stricture/IIIa/endoscopic urethrotomy | 1 (3) | – | |
| Epididymo-orchitis/II/Lead subacetate | 1 (3) | – | |
| +NSAIDs + quinolones + CIC | |||
| Urethro-rectal fistula/IIIb/Repair | – | 1 | |
| Urethral diverticulum/IIIb/bulbourethral sling | 1 (3) | – |
CIC, clean intermittent catheterisation.